RecruitingPhase 2NCT04063540

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura


Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

40 participants

Start Date

Aug 11, 2020

Study Type

INTERVENTIONAL

Summary

Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology of migraine making these channels a therapeutic target of migraine disease. The implication of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a mouse model, cortical spreading depression is inhibited by different Acid-Sensing Ion Channel blockers including amiloride which is a non-selective blocker of the Acid-Sensing Ion Channel-1 channel. From a translational perspective, an efficacy of amiloride on a series of migraine patients suffering from severe aura in open conditions. The APAM study is a proof-of-concept study that aims to evaluate the effect of amiloride in the prophylaxis of migraine with aura. This is a randomized crossover study versus placebo conducted in 3 French headache centers.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria6

  • Diagnosis of migraine with aura code
  • At least 1 aura with aura per month in the 3 months prior to inclusion
  • No prophylactic antimigraine treatment for at least 1 month prior to inclusion
  • For women of childbearing age, use of a reliable contraceptive method at least 3 months before and 1 month after the study
  • Signature of written informed consent
  • Patient affiliated with Social Security

Exclusion Criteria11

  • Existence of contraindication to taking amiloride:
  • Known hypersensitivity to the molecule
  • Hyperkalemia (potassium level (> 5.5 mmol / l))
  • Use of another hyperkalemic diuretic or potassium salts
  • Renal insufficiency (clearance <60 ml / min)
  • Severe hepatocellular insufficiency
  • In combination with lithium, converting enzyme inhibitors, angiotensin II inhibitors (except if there is hypokalemia), ciclosporin, tacrolimus, non-antiarrhythmic drugs giving torsades de pointes
  • Cardiovascular and renal history, for subjects over 75 years old
  • Patient, who from an investigator's point of view would not be compliant to the procedure of the study
  • Pregnant or lactating patient
  • Patient under trusteeship, under guardianship, protected by law

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAmiloride

Treatment by Amiloride vs placebo in crossover

DRUGPlacebos

Treatment by Amiloride vs placebo in crossover


Locations(5)

Hôpital Pierre Wertheimer

Bron, France

CHU Gabriel Montpied

Clermont-Ferrand, France

AP-HM

Marly, France

CHU de Montpellier

Montpellier, France

CHU de NICE

Nice, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04063540